Information for Healthcare Professionals
FORCE supports healthcare professionals
If you're a healthcare professional caring for individuals and families affected by hereditary cancer, FORCE has evidence-informed tools, education and support resources to facilitate shared decision-making, and compassionate, informed care to help.
Help Your Patients Find Support
FORCE support programs include virtual community meetings, trained guidance from peer navigators and community message boards. We offer your patients multiple ways to connect with others in a safe, supportive environment. Download our flyer with all our support programs.
Support Meetings & Events
FORCE's Support Meetings and Events Calendar provides details on upcoming support meetings, webinars and partner events.
1 to 1 Support & Navigation
FORCE's Peer Navigation Program connects those seeking support with a trained peer navigator who shares a similar experience.
Spotlight
Looking for the latest guidelines?
FORCE provides gene-specific summaries on cancer risk, screening, prevention and treatment guidelines, and resources for individuals with inherited cancer risk.
Customizable Resources
Add your logo and contact info to FORCE materials
FORCE’s resource center allows you to personalize FORCE publications and genetic test result disclosure letters with your contact information and logo for printing or sharing on demand. We also provide links and QR codes to curated content for specific genes, which you can use within your own materials.
Insurance Coverage & Appeals
Find information on insurance coverage and reimbursement for health insurance appeals. Our customizable insurance appeal letters are designed to help you and your patients quickly appeal insurance denials.
Find Research Studies Enrolling People with Inherited Mutations
Use our search and enroll tool to connect your patients to the latest cancer prevention, treatment and quality-of-life studies enrolling people with or at high risk for hereditary cancers.
This study is testing a new targeted drug called daraxonrasib to see if it helps people with metastatic pancreatic cancer live longer or keep their cancer from growing longer than standard chemotherapy alone. Researchers are...
This study tests whether COM701 (an anti‑PVRIG immunotherapy) given every 3 weeks as maintenance can delay cancer growth after a good response to platinum chemotherapy. Adults with relapsed platinum‑sensitive ovarian, fallopian tube, or primary peritoneal...
This trial will study the safety, tolerability, and initial effectiveness of MOMA-341, a new type of targeted therapy, alone or in combination with a standard chemotherapy (irinotecan) or together with an immunotherapy to treat people...
Go Behind the Headlines
Force's XRAY program shares easy-to-understand information on the latest cancer research.
Update : FDA grants expanded access to an investigational drug for pancreatic cancer
The U.S. Food and Drug Administration (FDA) granted expanded access to the investigational drug daraxonrasib for people with previously treated pancreatic cancer. This allows more access to the drug outside of a clinical trial, even...
Study : Males with prostate cancer share positive experiences with genetic testing
A study of men with prostate cancer found that most had a positive experience with genetic testing. Many reported feeling more informed about their health and understanding their cancer risks after receiving their results. (posted 5/26/2026)
Study : Breast cancer risk after ovarian cancer in women with BRCA mutations
Women who have an inherited mutation in BRCA1 or BRCA2 have a higher lifetime risk of developing breast and ovarian cancer compared to women without these mutations. This study found that after being diagnosed with...
Quickly share FORCE resources with just a few clicks!
FORCE’s Healthcare Provider Toolkit makes it easy to distribute resources across your favorite social media platforms.